Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Bioxcel Therapeutics Inc
(NQ:
BTAI
)
2.570
+0.010 (+0.39%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Bioxcel Therapeutics Inc
< Previous
1
2
3
4
5
6
7
8
Next >
Why Is Cormedix (CRMD) Stock Down 23% Today?
June 29, 2023
Cormedix (CRMD) stock is falling hard on Thursday with heavy trading after the company priced a public offering of its shares.
Via
InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
June 29, 2023
Via
Benzinga
Why Is BioXcel Therapeutics (BTAI) Stock Down 57% Today?
June 29, 2023
BioXcel Therapeutics (BTAI) stock is taking a beating on Thursday after the company released its latest clinical trial data.
Via
InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
June 29, 2023
We're starting Thursday with a detailed look at all of the biggest pre-market stock movers worth keeping an eye on today!
Via
InvestorPlace
Goldman Sachs Maintains Neutral Rating for BioXcel Therapeutics: Here's What You Need To Know
May 26, 2023
Via
Benzinga
Where BioXcel Therapeutics Stands With Analysts
May 26, 2023
Via
Benzinga
Why Shares of BioXcel Therapeutics Are Dropping Thursday
May 25, 2023
A trial for one of the company's therapies didn't meet its primary endpoint.
Via
The Motley Fool
Looking Into BioXcel Therapeutics's Return On Capital Employed
May 22, 2023
Via
Benzinga
BioXcel CEO Vimal Mehta Says This Alzheimer's News Is A 'Huge Win For Society'
June 29, 2023
The company hopes to soon gain approval to treat patients with agitation due to Alzheimer's disease.
Via
Investor's Business Daily
3 Short-Squeeze Stocks Set for a Spectacular Gamma Squeeze Rally
June 15, 2023
If you can’t stand a dull day at the trading desk, these short-squeeze stocks to buy could spike your blood pressure and your portfolio.
Via
InvestorPlace
12 Health Care Stocks Moving In Thursday's Intraday Session
May 25, 2023
Via
Benzinga
BioXcel Therapeutics Stock Tumbles: Company Releases Mixed Results From Lower Dose Igalmi Study In Bipolar/Schizophrenia Associated Agitation
May 25, 2023
Via
Benzinga
BioXcel Stock Crashes 22% As Bid To Double Its Market Appears Less Certain
May 25, 2023
The company is hoping to double its market opportunity. But that looks less certain.
Via
Investor's Business Daily
BioXcel Therapeutics Reports Encouraging Phase 1b Results For Innovative Depression Treatment
May 16, 2023
BioXcel Therapeutics Inc (NASDAQ: BTAI) announced topline data from its Phase 1b multiple ascending dose (MAD) trial of BXCL501 (dexmedetomidine) sublingual film, for agitation associated with...
Via
Benzinga
The Latest Analyst Ratings for BioXcel Therapeutics
May 09, 2023
Via
Benzinga
Why BioXcel Therapeutics Stock Marched Higher Today
May 08, 2023
The biotech's Q1 earnings report set the stage for a flurry of important clinical updates in the coming months.
Via
The Motley Fool
BioXcel Therapeutics's Earnings Outlook
May 05, 2023
Via
Benzinga
Why Dollar Tree Shares Are Trading Lower By 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
May 25, 2023
Gainers Beamr Imaging Ltd. (NASDAQ: BMR) shares climbed 211.6% to $6.86 after NVIDIA announced the release of NVENC Video Codec SDK 12.1 showcasing the integration with Beamr CABR.
Via
Benzinga
Why These 3 Nasdaq Stocks Were Glowing Green This Week
May 11, 2023
These three biopharmaceutical stocks rocketed higher this week.
Via
The Motley Fool
6 Analysts Have This to Say About BioXcel Therapeutics
March 10, 2023
Via
Benzinga
Earnings Preview: BioXcel Therapeutics
March 08, 2023
Via
Benzinga
Expert Ratings for BioXcel Therapeutics
February 08, 2023
Via
Benzinga
BioXcel Earnings Miss Q1 Estimates Due To Higher Costs, Expects Uptick In Revenues
May 08, 2023
BioXcel Therapeutics, Inc. (NASDAQ: BTAI) reported first-quarter FY23 revenues of $206,000,
Via
Benzinga
Axsome Surges As Its Newest Product Shines. But BioXcel Does The Opposite.
May 08, 2023
Axsome shares are nearing a breakout point. But BioXcel crumbled on its report.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Monday's Pre-Market Session
May 08, 2023
Via
Benzinga
The Next Evolution In Drugs? It's Artificial Intelligence, Says This CEO
May 04, 2023
This company is hoping to execute for a second time on its moonshot goal.
Via
Investor's Business Daily
Meta Platforms To Rally Over 26%? Here Are 10 Other Analyst Forecasts For Tuesday
March 21, 2023
Morgan Stanley boosted the price target for HubSpot, Inc. (NYSE: HUBS) from $447 to $466. Morgan Stanley analyst Keith Weiss maintained an Overweight rating. HubSpot shares fell 1.9% to close at...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 10, 2023
March 10, 2023
Via
Benzinga
BioXcel Therapeutics Unveils Complete Data From BXCL701/Keytruda Combo Study In Prostate Cancer Subtype
February 14, 2023
Via
Benzinga
Analyst Reiterates This Alzheimer's Candidate As Top Idea For 2023
February 08, 2023
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.